Vertex Pharmaceuticals Incorporated VRTX announced today new data
from a long-term follow-up study that showed that the improvements in lung
function (forced expiratory volume in one second, FEV[1]), respiratory
symptoms and weight gain among people who were treated with KALYDECO™
(ivacaftor)for 48 weeks in one of two pivotal studies (STRIVE or ENVISION)
were durable for up to 96 total weeks of treatment
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in